KRAS and lung cancer: The effect of the combination of lovastatin with gefitinib on gefitinib-resistant human nonsmall-cell lung cancer (NSCLC) A549 and NCI-H460 cell lines with K-ras mutations has shown to effectively downregulate K-ras protein and suppress the Raf, ERK1/2, AKT, and EGFR phosphorylation in both cell lines [20].